🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

Director Julie Smith Sells 27,280 Shares of Exelixis Inc (EXEL)

Published 2024-05-23, 08:34 p/m
Director Julie Smith Sells 27,280 Shares of Exelixis Inc (EXEL)
EXEL
-

GuruFocus - On May 21, 2024, Julie Smith, Director at Exelixis Inc (NASDAQ:EXEL), executed a sale of 27,280 shares of the company. The transaction was filed on the same day with the SEC. Following this transaction, the insider now owns 5,445 shares of Exelixis Inc.

Exelixis Inc is a biotechnology company focused on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers. The company is known for its product Cabometyx, which is used in the treatment of various forms of cancer including renal cell carcinoma and hepatocellular carcinoma.

Over the past year, the insider transaction history at Exelixis Inc shows a trend with 2 insider buys and 14 insider sells. Julie Smith has sold a total of 27,280 shares and purchased 0 shares during this period.

On the date of the recent transaction, shares of Exelixis Inc were trading at $21.12, giving the company a market cap of $5.95 billion. The price-earnings ratio of the stock stands at 31.74, which is above the industry median of 28.25.

The stock is currently considered Modestly Undervalued with a price-to-GF-Value ratio of 0.88, based on a GF Value of $23.95. The GF Value is calculated considering historical trading multiples, an adjustment factor based on past returns and growth, and future business performance estimates.

This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.

This content was originally published on Gurufocus.com

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.